Shareholders Equity: The sum of preferred and common equity items.
Kairos Pharma, Ltd. (KAPA) had Shareholders Equity of $6.34M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-1.36M |
|
-- |
|
-- |
|
$1.42M |
|
$-1.42M |
|
$0.05M |
|
$-1.36M |
|
$-1.36M |
|
$-1.36M |
|
$-1.36M |
|
$-1.36M |
|
$-1.36M |
|
$-1.42M |
|
$-1.16M |
|
18.43M |
|
18.43M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$5.39M |
|
-- |
|
$1.15M |
|
$6.54M |
|
$0.20M |
|
-- |
|
-- |
|
$0.20M |
|
$6.34M |
|
$6.28M |
|
|
Shareholders Equity |
$6.34M |
20.82M |
|
| Cash Flow Statement Financials | |
$-3.44M |
|
-- |
|
$6.66M |
|
$1.27M |
|
$4.49M |
|
$3.22M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
27.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.44M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.53% |
|
-21.74% |
|
-20.87% |
|
-21.53% |
|
$0.30 |
|
$-0.19 |
|
$-0.19 |
|